ClinicalTrials.gg
Active, not recruitingNCT07104383Updated Apr 7, 2026

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

A Phase 3 interventional study of VK2735 in Weight Loss, sponsored by Viking Therapeutics, Inc.. Active, not recruiting at 127 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Viking Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.

Planned enrollment
21st of 915
1,100 · median 72
Started
2025
with 54 others
Phase 3
32 of 998
3 open now
Primary completion
2027-07
later than 82 of 171 live
Registered
933rd of 998
by date

Among the 998 studies in Weight Loss with a site in United States, this one is the 21st largest by planned enrollment of the 915 interventional ones that give a count, is one of 55 that started in 2025, is one of 32 in phase 3, reaches primary completion later than 82 of the 171 other live ones, and was the 933rd registered.

Weight Loss

1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.

Browse Weight Loss studies →

Open to participants now

117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

112 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 998 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight

03

Conditions studied

  • Weight Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age at the time of signing the
  2. (BMI) ≥27 kg/m2
  3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association with ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Type 2 diabetes mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists

Exclusion criteria

Exclusion Criteria:

  1. History of or current medical disorder that, in the opinion of the Investigator, does not support study participation
  2. Self-reported body weight change of 5% or more within 3 months of screening
  3. Have a prior or planned surgical treatment for obesity (except for liposuction or abdominoplasty if performed >1 year prior to screening)
  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  5. Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 diabetes mellitus (T2DM)
  6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

    • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL
  7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
  8. Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
  9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  10. History of acute or chronic pancreatitis
  11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Assignment

    VK2735 Placebo Comparator Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #1)

    VK2735 7.5mg Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #2)

    VK2735 12.5mg Once Weekly

    Drug: VK2735

  • Experimental
    Active Assignment (Dose #3)

    VK2735 17.5mg Once Weekly

    Drug: VK2735

Interventions

  • DrugVK2735

    VK2735 is a peptide GLP-1 and GIP dual agonist administered Once Weekly

06

What researchers measure

Primary outcomes

  1. Percent change in body weight from baseline to Week 78 in body weight

    Time frame: 78 Weeks

Secondary outcomes

  1. Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment

    Time frame: 78 Weeks

07

Study locations

127 sites
  • Viking Clinical Site #2037
    Birmingham, Alabama 35235, United States
  • Viking Clinical Site #2064
    Birmingham, Alabama 35249, United States
  • Viking Clinical Site #2128
    Huntsville, Alabama 35801, United States
  • Viking Clinical Site #2005
    Chandler, Arizona 85210, United States
  • Viking Clinical Site #2017
    Flagstaff, Arizona 86001, United States
  • Viking Clinical Site #2018
    Peoria, Arizona 85381, United States
  • Viking Clinical Site #2135
    Scottsdale, Arizona 85260, United States
  • Viking Clinical Site #2019
    Tucson, Arizona 85711, United States
  • Viking Clinical Site #2036
    Little Rock, Arkansas 72211, United States
  • Viking Clinical Site #2071
    Chula Vista, California 91911, United States
  • Viking Clinical Site #2070
    Escondido, California 92025, United States
  • Viking Clinical Site #2054
    Huntington Park, California 90255, United States
  • Viking Clinical Site #2014
    Lake Forest, California 92630, United States
  • Viking Clinical Site #2129
    Lemon Grove, California 91945, United States
  • Viking Clinical Site #2051
    Lincoln, California 95648, United States
  • Viking Clinical Site #2050
    Long Beach, California 90815, United States
  • Viking Clinical Site #2078
    Manteca, California 95336, United States
  • Viking Clinical Site #2053
    Montclair, California 91763, United States
  • Viking Clinical Site #2068
    Panorama City, California 91402, United States
  • Viking Clinical Site #2132
    Rolling Hills Estates, California 90274, United States
  • Viking Clinical Site #2131
    San Diego, California 92103, United States
  • Viking Clinical Site #2052
    Spring Valley, California 91978, United States
  • Viking Clinical Site #2109
    Tustin, California 92780, United States
  • Viking Clinical Site #2067
    Van Nuys, California 91405, United States
  • Viking Clinical Site #2079
    Walnut Creek, California 94598, United States
  • Viking Clinical Site #2119
    Denver, Colorado 80210, United States
  • Viking Clinical Site #2013
    Clearwater, Florida 33756, United States
  • Viking Clinical Site #2121
    Clearwater, Florida 33761, United States
  • Viking Clinical Site #2003
    Cooper City, Florida 33024, United States
  • Viking Clinical Site #2112
    DeLand, Florida 32720, United States
  • Viking Clinical Site #2107
    Delray Beach, Florida 33445, United States
  • Viking Clinical Site #2083
    Fort Myers, Florida 33912, United States
  • Viking Clinical Site #2058
    Jacksonville, Florida 32216, United States
  • Viking Clinical Site #2076
    Lakeland, Florida 33803, United States
  • Viking Clinical Site #2060
    Lakewood Rch, Florida 34211, United States
  • Viking Clinical Site #2117
    Miami, Florida 33122, United States
  • Viking Clinical Site #2012
    Ocoee, Florida 34761, United States
  • Viking Clinical Site #2056
    Palmetto Bay, Florida 33157, United States
  • Viking Clinical Site #2011
    Port Orange, Florida 32127, United States
  • Viking Clinical Site #2057
    West Palm Beach, Florida 33407, United States
  • Viking Clinical Site #2116
    Atlanta, Georgia 30329, United States
  • Viking Clinical Site #2030
    Columbus, Georgia 31904, United States
  • Viking Clinical Site #2120
    Rincon, Georgia 31326, United States
  • Viking Clinical Site #2093
    Savannah, Georgia 31406, United States
  • Viking Clinical Site #2025
    Woodstock, Georgia 30189, United States
  • Viking Clinical Site #2062
    Honolulu, Hawaii 96814, United States
  • Viking Clinical Site #2080
    Meridian, Idaho 83642, United States
  • Viking Clinical Site #2006
    Chicago, Illinois 60607, United States
  • Viking Clinical Site #2146
    Indianapolis, Indiana 46202, United States
  • Viking Clinical Site #2127
    Valparaiso, Indiana 46383, United States
  • Viking Clinical Site #2147
    Sioux City, Iowa 68776, United States
  • Viking Clinical Site #2022
    West Des Moines, Iowa 50266, United States
  • Viking Clinical Site #2099
    Wichita, Kansas 67207, United States
  • Viking Clinical Site #2069
    Lexington, Kentucky 40509, United States
  • Viking Clinical Site #2040
    Lexington, Kentucky 40513, United States
  • Viking Clinical Site #2009
    Louisville, Kentucky 40213, United States
  • Viking Clinical Site #2118
    Baton Rouge, Louisiana 70808, United States
  • Viking Clinical Site #2139
    Baton Rouge, Louisiana 70809, United States
  • Viking Clinical Site #2106
    Lafayette, Louisiana 70508, United States
  • Viking Clinical Site #2020
    Metairie, Louisiana 70006, United States
  • Viking Clinical Site #2087
    Monroe, Louisiana 71201, United States
  • Viking Clinical Site #2094
    Chevy Chase, Maryland 20815, United States
  • Viking Clinical Site #2145
    Rockville, Maryland 20850, United States
  • Viking Clinical Site #2066
    Rockville, Maryland 20854, United States
  • Viking Clinical Site #2001
    Methuen, Massachusetts 01844, United States
  • Viking Clinical Site #2038
    Ypsilanti, Michigan 48197, United States
  • Viking Clinical Site #2140
    Gulfport, Mississippi 39503, United States
  • Viking Clinical Site #2031
    City of Saint Peters, Missouri 63303, United States
  • Viking Clinical Site #2016
    Kansas City, Missouri 64131, United States
  • Viking Clinical Site #2125
    Springfield, Missouri 65807, United States
  • Viking Clinical Site #2010
    Butte, Montana 59701, United States
  • Viking Clinical Site #2075
    Omaha, Nebraska 68134, United States
  • Viking Clinical Site #2035
    Las Vegas, Nevada 89148, United States
  • Viking Clinical Site #2034
    Reno, Nevada 89511, United States
  • Viking Clinical Site #2065
    Lebanon, New Hampshire 03756, United States
  • Viking Clinical Site #2095
    Marlton, New Jersey 08009, United States
  • Viking Clinical Site #2029
    Albuquerque, New Mexico 87109, United States
  • Viking Clinical Site #2088
    Albany, New York 12205, United States
  • Viking Clinical Site #2096
    Hartsdale, New York 10530, United States
  • Viking Clinical Site #2133
    New York, New York 10036, United States
  • Viking Clinical Site #2032
    Westfield, New York 14787, United States
  • Viking Clinical Site #2141
    Charlotte, North Carolina 28205, United States
  • Viking Clinical Site #2101
    Fayetteville, North Carolina 28304, United States
  • Viking Clinical Site #2026
    Greensboro, North Carolina 27410, United States
  • Viking Clinical Site #2110
    Morehead City, North Carolina 28557, United States
  • Viking Clinical Site #2061
    Morehead City, North Carolina 28857, United States
  • Viking Clinical Site #2115
    Winston-Salem, North Carolina 27157, United States
  • Viking Clinical Site #2027
    Fargo, North Dakota 58104, United States
  • Viking Clinical Site #2043
    Cincinnati, Ohio 45219, United States
  • Viking Clinical Site #2074
    Cincinnati, Ohio 45242, United States
  • Viking Clinical Site #2044
    Cleveland, Ohio 44122, United States
  • Viking Clinical Site #2089
    Columbus, Ohio 43215, United States
  • Viking Clinical Site #2148
    Dayton, Ohio 45420, United States
  • Viking Clinical Site #2113
    Norman, Oklahoma 73069, United States
  • Viking Clinical Site #2137
    Tulsa, Oklahoma 74133, United States
  • Viking Clinical Site #2097
    Portland, Oregon 97202, United States
  • Viking Clinical Site #2126
    Portland, Oregon 97210, United States
  • Viking Clinical Site #2045
    East Greenwich, Rhode Island 02818, United States
  • Viking Clinical Site #2028
    Greenville, South Carolina 29607, United States
  • Viking Clinical Site #2134
    Myrtle Beach, South Carolina 29572, United States

Showing the first 100 of 127 sites across 2 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.

Of 23 phase 3 interventional studies under Weight Loss, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 5, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Jul 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07104383
Responsible party
Sponsor
First posted
Aug 5, 2025
Start date
Jun 23, 2025
Primary completion
Jul 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Apr 7, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion